UroGen Pharma (NASDAQ:URGN) Issues Quarterly Earnings Results

UroGen Pharma (NASDAQ:URGN) issued its quarterly earnings data on Monday. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11), Zacks reports.

UroGen Pharma Price Performance

Shares of URGN opened at $9.71 on Monday. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The stock has a market cap of $227.83 million, a PE ratio of -3.09 and a beta of 1.12. The firm’s 50-day simple moving average is $10.45 and its two-hundred day simple moving average is $11.76. UroGen Pharma has a fifty-two week low of $9.03 and a fifty-two week high of $20.70.

Insider Transactions at UroGen Pharma

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares of the company’s stock, valued at $294,853.52. The trade was a 21.80 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on URGN shares. HC Wainwright reissued a “buy” rating and set a $64.00 target price on shares of UroGen Pharma in a research note on Tuesday, February 25th. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price objective for the company. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Tuesday, February 18th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $40.00.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.